Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO2004062642 - FORME POSOLOGIQUE A INNOCUITE PHARMACEUTIQUE

Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

[ EN ]

What is Claimed is:

1. A pharmaceutical safety dosage form comprising a phannaceutical and an antagonist for said pharmaceutical wherein said antagonist has significant bioavailability only when said pharmaceutical safety dosage form is disrupted.

2. The phannaceutical safety dosage of claim 1 wherein said pharmaceutical is adapted for time-release, or said antagonist comprises an insoluble coating, or both.

3. The pharmaceutical safety dosage fonn of claim 1 wherein said bioavailability occurs upon mechanical disraption.

4. The phannaceutical safety dosage fonn of claim 1 wherein said bioavailability occurs upon extraction by a chemical.

5. The pharmaceutical safety dosage form of claim 1 adapted to be administered orally.

6. The pharmaceutical safety dosage form of claim 1 adapted to be administered rectally, parenterally, vaginally, transdermally, intranasally, or via aerosol.

7. The pharmaceutical safety dosage fonn of claim 1 wherein said antagonist comprises an emetic agent.

8. The pharmaceutical safety dosage form of claim 7 wherein said emetic agent is ipecac or derivatives thereof.

9. The pharmaceutical safety dosage form of claim 1 wherein said pharmaceutical comprises a narcotic.

10. The pharmaceutical safety dosage form of claim 9 wherein said narcotic is codeine, oxycodone, propoxyphene, pentazocine, derivatives thereof, or combinations thereof.

11. The pharmaceutical safety dosage fonn of claim 9 wherein said antagonist is naloxone, nalmefene, derivatives thereof, or combinations thereof.

12. The pharmaceutical safety dosage form of claim 1 wherein said pharmaceutical comprises a sympathomimetic.

13. The phannaceutical safety dosage fonn of claim 12 further comprising an antil istamine.

14. The pharmaceutical safety dosage form of claim 13 wherein said sympathomimetic is pseudoephedrine HCl or derivatives thereof, and said antiliistamine is cetirizine HCl, fexofenadine HCl, derivatives thereof, or combinations thereof.

15. The pharmaceutical safety dosage fonn of claim 13 wherein said antagonist comprises an adrenergic beta blocker.

16. The pharmaceutical safety dosage fonn of claim 12 wherein said sympathomimetic comprises methylphenidate.

17. The pharmaceutical safety dosage form of claim 16 wherein said antagonist comprises an adrenergic beta blocker.

18. The pharmaceutical safety dosage fonn of claim 12 wherein said sympathomimetic comprises an amphetamine.

19. The pharmaceutical safety dosage form of claim 18 wherein said amphetamine is methamphetamine, amphetamine, dextroamphetamine, derivatives thereof, or combinations thereof.

20. The phannaceutical safety dosage fonn of claim 18 wherein said antagonist comprises an adrenergic beta blocker.

21. The pharmaceutical safety dosage form of claim 20 wherein said adrenergic beta blocker is propranolol, ateήolol, metoprolol, derivatives thereof, or combinations thereof.

22. The pharmaceutical safety dosage form of claim 1 wherein said pharmaceutical comprises a blood pressure-lowering medication.

23. The pharmaceutical safety dosage fonn of claim 22 wherein said blood pressure-lowering medication is an adrenergic beta blocker, a calcium channel blocker, or an ACE inhibitor.

24. The pharmaceutical safety dosage form of claim 23 wherein said blood pressure-lowering medication is propranolol, metoprolol, nifedipine, diltiazem, nisoldipine, timolol maleate, derivatives thereof, or combinations thereof.

25. The pharmaceutical safety dosage fonn of claim 22 wherein said antagonist comprises a sympathomimetic.

26. The pharmaceutical safety dosage form of claim 25 wherein said sympathomimetic is dop amine, epinepherine, derivatives thereof, or combinations thereof.

27. The pharmaceutical safety dosage form of claim 1 wherein said pharmaceutical comprises a hypoglycemic agent.

28. The pharmaceutical safety dosage form of claim 27 wherein said hypoglycemic agent is insulin, metformin, glipizide, glyburide, derivatives thereof, or combinations thereof.

29. The pharmaceutical safety dosage form of claim 27 wherein said antagonist comprises a hyperglycemic agent.

30. The pharmaceutical safety dosage fonn of claim 29 wherein said hyperglycemic agent is epinepherine, glucagon, derivatives thereof, or combinations thereof.

31. A pharmaceutical safety dosage form comprising a pharmaceutical contained within a first microdosage form, said first microdosage form being adapted for release of said pharmaceutical within a patient, together with an antagonist for said pharmaceutical, said antagonist being contained within a second microdosage form, said second microdosage form being substantially insoluble in gastric fluid.

32. The pharmaceutical safety dosage form of claim 31 wherein said pharmaceutical is adapted for time-release, or said second microdosage form comprises a coating which is substantially insoluble in gastric fluid, or both.

33. The phannaceutical safety dosage fonn of claim 31 wherein said first microdosage form comprises beads, tablets, mini tablets, or combinations thereof; or second microdosage forms comprises beads, tablets, mini tablets, or combinations thereof; or both.

34. The pharmaceutical safety dosage form of claim 31 adapted to be administered orally.

35. The pharmaceutical safety dosage form of claim 31 adapted to be administered rectally, parenterally, vaginally, transdermally, intranasally, or via aerosol.

36. The pharmaceutical safety dosage form of claim 31 wherein said antagonist comprises an emetic agent.

37. The pharmaceutical safety dosage form of claim 36 wherein said emetic agent is ipecac or derivatives thereof.

38. The pharmaceutical safety dosage form of claim 31 wherein said pharmaceutical comprises a narcotic.

39. The phannaceutical safety dosage form of claim 38 wherein said narcotic is codeine, oxycodone, propoxyphene, pentazocine, derivatives thereof, or combinations thereof.

40. The pharmaceutical safety dosage form of claim 38 wherein said antagonist is naloxone, nalmefene, derivatives thereof, or combinations thereof.

41. The pharmaceutical safety dosage fonn of claim 31 wherein said pharmaceutical comprises a sympathomimetic.

42. The pharmaceutical safety dosage form of claim 41 further comprising an antihistamme.

43. The pharmaceutical safety dosage form of claim 42 wherein said sympathomimetic is pseudoephedrine HCl or derivatives thereof, and said antihistamme is cetirizine HCl, fexofenadine HCl, derivatives thereof, or combinations thereof.

44. The pharmaceutical safety dosage form of claim 42 wherein said antagonist comprises an adrenergic beta blocker.

45. The pharmaceutical safety dosage fonn of claim 41 wherein said sympathomimetic comprises methylphenidate.

46. The phannaceutical safety dosage form of claim 45 wherein said antagonist comprises an adrenergic beta blocker.

47. The phannaceutical safety dosage fonn of claim 41 wherein said sympathomimetic comprises an amphetamine.

48. The pharmaceutical safety dosage form of claim 47 wherein said amphetamine is methamphetamine, amphetamine, dextroamphetamine, derivatives thereof, or combinations thereof.

49. The pharmaceutical safety dosage form of claim 47 wherein said antagonist comprises an adrenergic beta blocker.

50. The pharmaceutical safety dosage fonn of claim 49 wherein said adrenergic beta blocker is propranolol, atenolol, metoprolol, derivatives thereof, or combinations thereof.

51. The pharmaceutical safety dosage form of claim 31 wherein said pharmaceutical comprises a blood pressure-lowering medication.

52. The pharmaceutical safety dosage form of claim 51 wherein said blood pressure-lowering medication is an adrenergic beta blocker, a calcium channel blocker, or an ACE inhibitor.

53. The pharmaceutical safety dosage fonn of claim 52 wherein said blood pressure-lowering medication is propranolol, metoprolol, nifedipine, diltiazem, nisoldipine, timolol maleate, derivatives thereof, or combinations thereof.

54. The pharmaceutical safety dosage fonn of claim 51 wherein said antagonist comprises a sympathomimetic.

55. The pharmaceutical safety dosage form of claim 54 wherein said sympathomimetic is dopamine, epinepherine, derivatives thereof, or combinations thereof.

56. The pharmaceutical safety dosage form of claim 31 wherein said pharmaceutical comprises a hypoglycemic agent.

57. The phannaceutical safety dosage fonn of claim 56 wherein said hypoglycemic agent is insulin, metformin, glipizide, glyburide, derivatives thereof, or combinations thereof.

58. The pharmaceutical safety dosage form of claim 56 wherein said antagonist comprises a hyperglycemic agent.

59. The phannaceutical safety dosage fonn of claim 58 wherein said hyperglycemic agent is epinepherine, glucagon, derivatives thereof, or combinations thereof.

60. A pharmaceutical safety dosage fonn comprising a pharmaceutical contained within a first plurality of particulated forms, said first particulated forms being adapted for release of said pharmaceutical within a patient, together with an antagonist for said pharmaceutical, said antagonist being contained within a second plurality of particulated fonns, said second particulated forms being substantially insoluble in gastric fluid.

61. The pharmaceutical safety dosage form of claim 60 wherein said pharmaceutical is adapted for time-release, or said second plurality of particulated fonns comprise a polymorph or a solvate which is substantially insoluble in gastric fluid, or both.

62. The pharmaceutical safety dosage fonn of claim 61 wherein said first plurality of particulated forms comprises a sustained-release powder.

63. The phannaceutical safety dosage fonn of claim 60 adapted to be administered orally.

64. The pharmaceutical safety dosage form of claim 60 adapted to be administered rectally, parenterally, vaginally, transdermally, intranasally, or via aerosol.

65. The pharmaceutical safety dosage form of claim 60 wherein said antagonist comprises an emetic agent.

66. The pharmaceutical safety dosage form of claim 65 wherein said emetic agent is ipecac or derivatives thereof.

67. The pharmaceutical safety dosage fonn of claim 60 wherein said pharmaceutical comprises a narcotic.

68. The phannaceutical safety dosage fonn of claim 67 wherein said narcotic is codeine, oxycodone, propoxyphene, pentazocine, derivatives thereof, or combinations thereof.

69. The pharmaceutical safety dosage form of claim 67 wherein said antagonist is naloxone, nalmefene, derivatives thereof, or combinations thereof.

70. The pharmaceutical safety dosage form of claim 60 wherein said pharmaceutical comprises a sympathomimetic.

71. The pharmaceutical safety dosage fonn of claim 70 further comprising an antihistamine.

72. The pharmaceutical safety dosage form of claim 71 wherein said sympathomimetic is pseudoephedrine HCl or derivatives thereof, and said antihistamine is cetirizine HCl, fexofenadine HCl, derivatives thereof, or combinations thereof.

73. The pharmaceutical safety dosage fonn of claim 71 wherein said antagonist comprises an adrenergic beta blocker.

74. The pharmaceutical safety dosage form of claim 70 wherein said sympathomimetic comprises methylphenidate.

75. The pharmaceutical safety dosage form of claim 74 wherein said antagonist comprises an adrenergic beta blocker.

76. The pharmaceutical safety dosage form of claim 70 wherein said sympathomimetic comprises an amphetamine.

77. The pharmaceutical safety dosage fonn of claim 76 wherein said amphetamine is methamphetamine, amphetamine, dextroamphetamine, derivatives thereof, or combinations thereof.

78. The phannaceutical safety dosage fonn of claim 76 wherein said antagonist comprises an adrenergic beta blocker.

79. The pharmaceutical safety dosage form of claim 78 wherein said adrenergic beta blocker is propranolol, atenolol, metoprolol, derivatives thereof, or combinations thereof.

80. The phannaceutical safety dosage fonn of claim 60 wherein said pharmaceutical comprises a blood pressure-lowering medication.

81. The pharmaceutical safety dosage form of claim 80 wherein said blood pressure-lowering medication is an adrenergic beta blocker, a calcium chaimel blocker, or an ACE inhibitor.

82. The phannaceutical safety dosage fonn of claim 81 wherein said blood pressure-lowering medication is propranolol, metoprolol, nifedipine, diltiazem, nisoldipine, timolol maleate, derivatives thereof, or combinations thereof.

83. The pharmaceutical safety dosage form of claim 80 wherein said antagonist comprises a sympathomimetic.

84. The pharmaceutical safety dosage form of claim 83 wherein said sympathomimetic is dopamine, epinepherine, derivatives thereof, or combinations thereof.

85. The pharmaceutical safety dosage form of claim 60 wherein said pharmaceutical comprises a hypoglycemic agent.

86. The pharmaceutical safety dosage fonn of claim 85 wherein said hypoglycemic agent is insulin, metformin, glipizide, glyburide, derivatives thereof, or combinations thereof.

87. The pharmaceutical safety dosage form of claim 85 wherein said antagonist comprises a hyperglycemic agent.

88. The phannaceutical safety dosage fonn of claim 87 wherein said hyperglycemic agent is epinepherine, glucagon, derivatives thereof, or combinations thereof.

89. A pharmaceutical safety dosage fonn comprising a pharmaceutical contained within a microdosage fonn, said microdosage form being adapted for release of said pharmaceutical within a patient, together with an antagonist for said pharmaceutical, said antagonist being contained within a plurality of particulated dosage forms, said particulated dosage forms being substantially insoluble in gastric fluid.

90. The pharmaceutical safety dosage form of claim 89 wherein said pharmaceutical is adapted for time-release, or said plurality of particulated forms comprise a polymorph which is substantially insoluble in gastric fluid, or both.

91. The pharmaceutical safety dosage form of claim 89 wherein said microdosage form comprises beads, tablets, mini tablets, or combinations thereof.

92. The phannaceutical safety dosage fonn of claim 89 adapted to be administered orally.

93. The pharmaceutical safety dosage form of claim 89 adapted to be administered rectally, parenterally, vaginally, transdermally, intranasally, or via aerosol.

94. The phannaceutical safety dosage form of claim 89 wherein said antagonist comprises an emetic agent.

95. The pharmaceutical safety dosage form of claim 94 wherein said emetic agent is ipecac or derivatives thereof.

96. The pharmaceutical safety dosage form of claim 89 wherein said phannaceutical comprises a narcotic.

97. The phannaceutical safety dosage form of claim 96 wherein said narcotic is codeine, oxycodone, propoxyphene, pentazocine, derivatives thereof, or combinations thereof.

98. The pharmaceutical safety dosage form of claim 96 wherein said antagonist is naloxone, nalmefene, derivatives thereof, or combinations thereof.

99. The pharmaceutical safety dosage form of claim 89 wherein said pharmaceutical comprises a sympathomimetic.

100. The pharmaceutical safety dosage form of claim 99 further comprising an antihistamine.

101. The pharmaceutical safety dosage form of claim 100 wherein said sympathomimetic is pseudoephedrine HCl or derivatives thereof, and said antihistamine is cetirizine HCl, fexofenadine HCl, derivatives thereof, or combinations thereof.

102. The pharmaceutical safety dosage form of claim 100 wherein said antagonist comprises an adrenergic beta blocker.

103. The pharmaceutical safety dosage fonn of claim 99 wherein said sympathomimetic comprises methylphenidate.

104. The pharmaceutical safety dosage form of claim 103 wherein said antagonist comprises an adrenergic beta blocker.

105. The pharmaceutical safety dosage fonn of claim 99 wherein said sympathomimetic comprises an amphetamine.

106. The pharmaceutical safety dosage form of claim 105 wherein said amphetamine is methamphetamine, amphetamine, dextroamphetamine, derivatives thereof, or combinations thereof.

107. The pharmaceutical safety dosage form of claim 105 wherein said antagonist comprises an adrenergic beta blocker.

108. The pharmaceutical safety dosage fonn of claim 107 wherein said adrenergic beta blocker is propranolol, atenolol, metoprolol, derivatives thereof, or combinations thereof.

109. The pharmaceutical safety dosage form of claim 89 wherein said phannaceutical comprises a blood pressure-lowering medication.

110. The pharmaceutical safety dosage fonn of claim 109 wherein said blood pressure-lowering medication is an adrenergic beta blocker, a calcium channel blocker, or an ACE inhibitor.

111. The pharmaceutical safety dosage form of claim 110 wherein said blood pressure-lowering medication is propranolol, metoprolol, nifedipine, diltiazem, nisoldipine, timolol maleate, derivatives thereof, or combinations thereof.

112. The pharmaceutical safety dosage form of claim 109 wherein said antagonist comprises a sympathomimetic.

113. The pharmaceutical safety dosage fonn of claim 112 wherein said sympathomimetic is dopamine, epinepherine, derivatives thereof, or combinations thereof.

114. The pharmaceutical safety dosage form of claim 89 wherein said phannaceutical comprises a hypoglycemic agent.

115. The phannaceutical safety dosage fonn of claim 114 wherein said hypoglycemic agent is insulin, metformin, glipizide, glyburide, derivatives thereof, or combinations thereof.

116. The pharmaceutical safety dosage fonn of claim 114 wherein said antagonist comprises a hyperglycemic agent.

117. The pharmaceutical safety dosage fonn of claim 116 wherein said hyperglycemic agent is epinepherine, glucagon, derivatives thereof, or combinations thereof.

118. A pharmaceutical safety dosage fonn comprising a pharmaceutical contained within a plurality of particulated forms, said particulated forms being adapted for release of said pharmaceutical within a patient, together with an antagonist for said pharmaceutical, said antagonist being contained within a microdosage form, said microdosage form being substantially insoluble in gastric fluid.

119. The phannaceutical safety dosage fonn of claim 118 wherein said plurality of particulated forms comprise a polymorph which is substantially insoluble in gastric fluid, or said microdosage form comprises a coating which is substantially insoluble in gastric fluid, or both.

120. The pharmaceutical safety dosage form of claim 118 wherein said microdosage form comprises beads, tablets, mini tablets, or combinations thereof.

121. The pharmaceutical safety dosage form of claim 118 adapted to be administered orally.

122. The pharmaceutical safety dosage fonn of claim 118 adapted to be administered rectally, parenterally, vaginally, transdeπnally, intranasally, or via aerosol.

123. The phannaceutical safety dosage form of claim 118 wherein said antagonist comprises an emetic agent.

124. The pharmaceutical safety dosage form of claim 123 wherein said emetic agent is ipecac or derivatives thereof.

125. The pharmaceutical safety dosage form of claim 118 wherein said pharmaceutical comprises a narcotic.

126. The pharmaceutical safety dosage fonn of claim 125 wherein said narcotic is codeine, oxycodone, propoxyphene, pentazocine, derivatives thereof, or combinations thereof.

127. The pharmaceutical safety dosage fonn of claim 125 wherein said antagonist is naloxone, nalmefene, derivatives thereof, or combinations thereof.

128. The pharmaceutical safety dosage form of claim 118 wherein said phannaceutical comprises a sympathomimetic.

129. The phannaceutical safety dosage form of claim 128 further comprising an antihistamine.

130. The pharmaceutical safety dosage form of claim 129 wherein said sympathomimetic is pseudoephedrine HCl or derivatives thereof, and said antihistamine is cetirizine HCl, fexofenadine HCl, derivatives thereof, or combinations thereof.

131. The pharmaceutical safety dosage form of claim 129 wherein said antagonist comprises an adrenergic beta blocker.

132. The pharmaceutical safety dosage form of claim 128 wherein said sympathomimetic comprises methylphenidate.

133. The pharmaceutical safety dosage form of claim 132 wherein said antagonist comprises an adrenergic beta blocker.

134. The pharmaceutical safety dosage fonn of claim 128 wherein said sympathomimetic comprises an amphetamine.

135. The phannaceutical safety dosage fonn of claim 134 wherein said amphetamine is methamphetamine, amphetamine, dextroamphetamine, derivatives thereof, or combinations thereof.

136. The pharmaceutical safety dosage fonn of claim 134 wherein said antagonist comprises an adrenergic beta blocker.

137. The pharmaceutical safety dosage fonn of claim 136 wherein said adrenergic beta blocker is propranolol, atenolol, metoprolol, derivatives thereof, or combinations thereof.

138. The pharmaceutical safety dosage form of claim 118 wherein said phannaceutical comprises a blood pressure-lowering medication.

139. The pharmaceutical safety dosage fonn of claim 138 wherein said blood pressure-lowering medication is an adrenergic beta blocker, a calcium channel blocker, or an ACE inhibitor.

140. The pharmaceutical safety dosage form of claim 139 wherein said blood pressure-lowering medication is propranolol, metoprolol, nifedipine, diltiazem, nisoldipine, timolol maleate, derivatives thereof, or combinations thereof.

141. The pharmaceutical safety dosage fonn of claim 138 wherein said antagonist comprises a sympathomimetic.

142. The pharmaceutical safety dosage fonn of claim 141 wherein said sympathomimetic is dopamine, epinepherine, derivatives thereof, or combinations thereof

143. The phannaceutical safety dosage form of claim 118 wherein said pharmaceutical comprises a hypoglycemic agent.

144. The phannaceutical safety dosage fonn of claim 143 wherein said hypoglycemic agent is insulin, metformin, glipizide, glyburide, derivatives thereof, or combinations thereof.

145. The pharmaceutical safety dosage form of claim 143 wherein said antagonist comprises a hyperglycemic agent.

146. The pharmaceutical safety dosage form of claim 145 wherein said hyperglycemic agent is epinepherine, glucagon, derivatives thereof, or combinations thereof.

147. A pharmaceutical safety dosage form comprising a pharmaceutical in a first form adjacent to an antagonist for said phannaceutical in a second fonn wherein said antagonist has significant bioavailability only when said phannaceutical safety dosage fonn is disrapted.

148. The phannaceutical safety dosage of claim 147 wherein said first form is time-release, or said second form comprises an insoluble coating, or both.

149. The pharmaceutical safety dosage form of claim 147 wherein said first fonn is substantially layered over said second form.

150. The pharmaceutical safety dosage form of claim 147 wherein said second form is substantially layered over said first form.

151. The phannaceutical safety dosage form of claim 147 wherein said bioavailability occurs upon mechanical disruption.

152. The pharmaceutical safety dosage fonn of claim 147 wherein said bioavailability occurs upon extraction by a chemical.

153. The phannaceutical safety dosage fonn of claim 147 adapted to be administered orally.

154. The pharmaceutical safety dosage form of claim 147 adapted to be administered rectally, parenterally, vaginally, transdermally, intranasally, or via aerosol.

155. The pharmaceutical safety dosage fonn of claim 147 wherein said antagonist comprises an emetic agent.

156. The pharmaceutical safety dosage form of claim 155 wherein said emetic agent is ipecac or derivatives thereof.

157. The phannaceutical safety dosage fonn of claim 147 wherein said phannaceutical comprises a narcotic.

158. The pharmaceutical safety dosage fonn of claim 157 wherein said narcotic is codeine, oxycodone, propoxyphene, pentazocine, derivatives thereof, or combinations thereof.

159. The pharmaceutical safety dosage form of claim 157 wherein said antagonist is naloxone, nalmefene, derivatives thereof, or combinations thereof.

160. The pharmaceutical safety dosage form of claim 147 wherein said pharmaceutical comprises a sympathomimetic.

161. The pharmaceutical safety dosage fonn of claim 160 further comprising an antihistamine.

162. The pharmaceutical safety dosage form of claim 161 wherein said sympathomimetic is pseudoephedrine HCl or derivatives thereof, and said antihistamine is cetirizine HCl, fexofenadine HCl, derivatives thereof, or combinations thereof.

163. The pharmaceutical safety dosage form of claim 161 wherein said antagonist comprises an adrenergic beta blocker.

164. The pharmaceutical safety dosage form of claim 160 wherein said sympathomimetic comprises methylphenidate.

165. The pharmaceutical safety dosage form of claim 164 wherein said antagonist comprises an adrenergic beta blocker.

166. The pharmaceutical safety dosage fonn of claim 160 wherein said sympathomimetic comprises an amphetamine.

167. The pharmaceutical safety dosage fonn of claim 166 wherein said amphetamine is methamphetamine, amphetamine, dextroamphetamine, derivatives thereof, or combinations thereof.

168. The pharmaceutical safety dosage fonn of claim 166 wherein said antagonist comprises an adrenergic beta blocker.

169. The pharmaceutical safety dosage form of claim 168 wherein said adrenergic beta blocker is propranolol, atenolol, metoprolol, derivatives thereof, or combinations thereof.

170. The phannaceutical safety dosage fonn of claim 147 wherein said pharmaceutical comprises a blood pressure-lowering medication.

171. The phannaceutical safety dosage fonn of claim 170 wherein said blood pressure-lowering medication is an adrenergic beta blocker, a calcium channel blocker, or an ACE inhibitor.

172. The pharmaceutical safety dosage fonn of claim 171 wherein said blood pressure-lowering medication is propranolol, metoprolol, nifedipine, diltiazem, nisoldipine, timolol maleate, derivatives thereof, or combinations thereof.

173. The pharmaceutical safety dosage form of claim 170 wherein said antagonist comprises a sympathomimetic.

174. The pharmaceutical safety dosage fonn of claim 173 wherein said sympathomimetic is dopamine, epinepherine, derivatives thereof, or combinations thereof.

175. The phannaceutical safety dosage form of claim 147 wherein said phannaceutical comprises a hypoglycemic agent.

176. The pharmaceutical safety dosage fonn of claim 175 wherein said hypoglycemic agent is insulin, metfonnin, glipizide, derivatives thereof, or combinations thereof.

177. The pharmaceutical safety dosage form of claim 175 wherein said antagonist comprises a hyperglycemic agent.

178. The pharmaceutical safety dosage fonn of claim 177 wherein said hyperglycemic agent is epinepherine, glucagon, derivatives thereof, or combinations thereof.

179. A method of administering a pharmaceutical comprising:
providing a pharmaceutical safety dosage fonn comprising a pharmaceutical in a first form, said first form providing a prescribed bioavailability; and
providing an antagonist for said phannaceutical in a second fonn, said second fonn providing insignificant bioavailability when administered; and
wherein disraption to said phannaceutical safety dosage form may result in significant bioavailability of said antagonist.

180. The method of claim 179 wherein said significant bioavailability occurs upon mechanical disruption.

181. The method of claim 179 wherein said significant bioavailability occurs upon extraction by a chemical.

182. The method of claim 179 wherein said pharmaceutical safety dosage form is adapted to be administered orally.

183. The method of claim 179 wherein said pharmaceutical safety dosage fonn is adapted to be administered rectally, parenterally, vaginally, transdennally, intranasally, or via aerosol.

184. The method of claim 179 wherein said antagonist comprises an emetic agent.

185. The method of claim 184 wherein said emetic agent is ipecac or derivatives thereof.

186. The method of claim 179 wherein said pharmaceutical comprises a narcotic.

187. The method of claim 186 wherein said narcotic is codeine, oxycodone, propoxyphene, pentazocine, derivatives thereof, or combinations thereof.

188. The method of claim 186 wherein said antagonist is naloxone, nalmefene, derivatives thereof, or combinations thereof.

189. The method of claim 179 wherein said phannaceutical comprises a sympathomimetic.

190. The method of claim 189 wherein said pharmaceutical safety dosage form further comprises an antihistamine.

191. The method of claim 190 wherein said sympathomimetic is pseudoephedrine HCl or derivatives thereof, and said antihistamine is cetirizine HCl, fexofenadine HCl, derivatives thereof, or combinations thereof.

192. The method of claim 190 wherein said antagonist comprises an adrenergic beta blocker.

193. The method of claun 189 wherein said sympathomimetic comprises methylphenidate.

194. The method of claim 193 wherein said antagonist comprises an adrenergic beta blocker.

195. The method of claim 189 wherein said sympathomimetic comprises an amphetamine.

196. The method of claim 195 wherein said amphetamine is methamphetamine, amphetamine, dextroamphetamine, derivatives thereof, or combinations thereof.

197. The method of claim 196 wherein said antagonist comprises an adrenergic beta blocker.

198. The method of claim 197 wherein said adrenergic beta blocker is propranolol, atenolol, metoprolol, derivatives thereof, or combinations thereof.

199. The method of claim 179 wherein said pharmaceutical comprises a blood pressure-lowering medication.

200. The method of claim 199 wherein said blood pressure-lowering medication is an adrenergic beta blocker, a calcium channel blocker, or an ACE inhibitor.

201. The method of claim 200 wherein said blood pressure-lowering medication is propranolol, metoprolol, nifedipine, diltiazem, nisoldipine, timolol maleate, derivatives thereof, or combinations thereof.

202. The method of claim 199 wherein said antagonist comprises a sympathomimetic.

203. The method of claim 202 wherein said sympathomimetic is dopamine, epinepherine, derivatives thereof, or combinations thereof.

204. The method of claim 179 wherein said pharmaceutical comprises a hypoglycemic agent.

205. The method of claim 204 wherein said hypoglycemic agent is insulin, metformin, glipizide, glyburide, derivatives thereof, or combinations thereof.

206. The method of claim 204 wherein said antagonist comprises a hyperglycemic agent.

207. The method of claim 206 wherein said hyperglycemic agent is epinepherine, glucagon, derivatives thereof, or combinations thereof.

208. A method of delivering a drag to a patient comprising placing said drug into a pharmaceutical safety dosage fonn further comprising an antagonist for said drag, said antagonist being insubstantially bioavailable when said dosage form is not disrapted; and administering said safety dosage form to the patient.

209. The method of claim 208 wherein said antagonist comprises an emetic agent.

210. The method of claim 209 wherein said emetic agent is ipecac or derivatives thereof.

211. A method of delivering a narcotic to a patient comprising placing said narcotic into a pharmaceutical safety dosage form further comprising a narcotic antagonist, said narcotic antagonist being insubstantially bioavailable when said dosage fonn is not disrapted; and administering said safety dosage form to the patient.

212. The method of claim 211 wherein said narcotic is codeine, oxycodone, propoxyphene, pentazocine, derivatives thereof, or combinations thereof.

213. The method of claim 211 wherein said antagonist is naloxone, nalmefene, derivatives thereof, or combinations thereof.

214. A method of delivering a sympathomimetic to a patient comprising placing said sympathomimetic into a phannaceutical safety dosage fonn further comprising an adrenergic beta blocker, said adrenergic beta blocker being insubstantially bioavailable when said dosage form is not disrupted; and administering said safety dosage form to the patient.

215. The method of claim 214 further delivering an antihistamine along with said sympathomimetic.

216. The method of claim 215 wherein said sympathomimetic and said antiliistamine are cetirizine HCl/pseudoephedrine HCl, fexofenadine HCl/pseudoephedrine HCl, derivatives thereof, or combinations thereof.

217. The method of claim 214 wherein said sympathomimetic comprises methylphenidate.

218. The method of claim 214 wherein said sympathomimetic comprises an amphetamine.

219. The method of claim 218 wherein said amphetamine is methamphetamine, amphetamine, dextroamphetamine, derivatives thereof, or combinations thereof.

220. The method of claim 219 wherein said adrenergic beta blocker is propranolol, atenolol, metoprolol, derivatives thereof, or combinations thereof.

221. A method of delivering a blood pressure-lowering medication to a patient comprising placing said blood-pressure lowering medication into a pharmaceutical safety dosage fonn further comprising a sympathomimetic, said sympathomimetic being insubstantially bioavailable when said dosage form is not disrupted; and administering said safety dosage form to the patient.

222. The method of claim 221 wherein said blood pressure-lowering medication is an adrenergic beta blocker, a calcium channel blocker, or an ACE inhibitor.

223. The method of claim 222 wherein said blood pressure-lowering medication is propranolol, metoprolol, nifedipine, diltiazem, nisoldipine, timolol maleate, derivatives thereof, or combinations thereof.

224. The method of claim 221 wherein said sympathomimetic is dopamine, epinepherine, derivatives thereof, or combinations thereof.

225. A method of delivering a hypoglycemic agent to a patient comprising placing said hypoglycemic agent into a pharmaceutical safety dosage form further comprising a hyperglycemic agent, said hyperglycemic agent being insubstantially bioavailable when said dosage form is not disrupted; and administering said safety dosage form to the patient.

226. The method of claim 225 wherein said hypoglycemic agent is insulin, metformin, glipizide, glyburide, derivatives thereof, or combinations thereof.

227. The method of claim 225 wherein said hyperglycemic agent is epinepherine, glucagon, derivatives thereof, or combinations thereof.

228. A method of making a phannaceutical safety dosage fonn comprising a pharmaceutical and an antagonist for said pharmaceutical wherein said antagonist has significant bioavailability only when said pharmaceutical safety dosage fonn is disrapted.